Dental Splint Cuts Sleep Apnea Severity in Half, Study Finds

Introduction

A dental splint that pushes the lower jaw forward cut sleep apnea severity roughly in half across 300 patients treated in a Swiss dental practice, according to new research from the University of Bern. The study, published in the Journal of Oral Rehabilitation, also challenges a common assumption: cranking the jaw further forward does not produce better results. Here is what the evidence says about mandibular advancement devices and where they fit in sleep apnea care.

How a Dental Splint Reopens a Collapsing Airway

Obstructive sleep apnea occurs when the tongue and soft tissues of the throat relax during sleep and block the upper airway. Each obstruction briefly wakes the brain — often without the sleeper noticing — fragmenting sleep and repeatedly dropping blood oxygen. The apnea-hypopnea index (AHI) counts these events per hour, while the oxygen desaturation index (ODI) tracks how often oxygen levels fall.

A mandibular advancement device works through simple mechanics: it holds the lower jaw in a forward position during sleep, which drags the tongue base forward with it and enlarges the airway behind it. Because the tongue is attached to the inner surface of the mandible, moving the jaw moves the tongue. The added airway volume reduces the suction pressures that cause collapse. CPAP remains the gold standard because it splints the airway open with pressurized air, but many patients cannot tolerate a mask night after night — and adherence is where MADs shine.

What the Bern Study Found: 50% Improvement, But Not From Bigger Bites

Bronwasser and colleagues at the University of Bern’s School of Dental Medicine reviewed polysomnography records from 300 OSA patients fitted with one of three MAD types — one conventionally manufactured and two designed with CAD/CAM technology. Average AHI fell by 16.4 ± 17.9 events per hour, and ODI dropped by 10.8 ± 15.2 — an improvement of approximately 50%.

Three findings stand out. First, baseline severity predicted response: patients who started with higher AHI and ODI values achieved the greatest reductions, meaning even severe patients can benefit substantially. Second, female gender and younger age were associated with larger improvements, echoing earlier observations that anatomy and tissue elasticity influence outcomes. Third, and perhaps most practically useful, more prominent protrusion did not increase benefit. Pushing the jaw further forward mainly adds jaw pain, bite changes, and morning discomfort — a real argument for careful, incremental titration rather than aggressive advancement.

The study has limits worth naming. It was retrospective, drew on patient files from a single private practice, and lacked a randomized comparison between device types. The conventionally manufactured device showed greater reductions, but the three device groups were not randomly assigned, so differences may reflect patient selection rather than the devices themselves.

When Splints Aren’t Enough: The Surgical Backstop

Some patients respond poorly to MADs or cannot tolerate CPAP at all. For that group, maxillofacial surgeons Ibrahim Malakuti and Pär Farzad at Karolinska University Hospital describe maxillomandibular advancement (MMA) in the Swedish medical journal Läkartidningen as a well-established alternative. The procedure moves both the upper and lower jaws forward, permanently enlarging the airway volume — essentially fixing the skeletal framework the MAD temporarily imitates.

Meta-analyses and long-term studies cited by the authors show AHI reductions exceeding 50%, frequently with full normalization of sleep parameters, improved quality of life, and high patient satisfaction. Yet the surgeons note MMA remains underutilized in Sweden despite appearing in international guidelines. Their message applies broadly: patients who fail first-line therapies should know surgical options exist rather than abandoning treatment altogether. Untreated OSA carries documented cardiovascular, metabolic, and neurocognitive risks — a concern also covered in our article on how your rest predicts heart disease risk.

What This Means If You’re Considering a MAD

For patients weighing options, the evidence supports a few practical conclusions:

• Expect meaningful improvement, not necessarily a cure. A 50% AHI reduction still leaves moderate patients above normal thresholds in many cases, so follow-up sleep testing matters.
• Tolerability drives success. A device you actually wear every night beats a theoretically more effective CPAP mask sitting in a drawer.
• Advancement distance should be titrated to the minimum effective position, since more protrusion adds side effects without added benefit.
• Combine therapies where sensible. Positional measures — such as side sleeping, which can cut apnea events roughly in half — may complement an oral device.
• If MAD and CPAP both fail, ask about surgical evaluation. Anatomy matters: patients with a narrow upper jaw or retrognathic profile often need structural solutions.

Drug therapy is also expanding the toolkit — incretin-based weight loss medications have shown measurable AHI reductions in trials — but oral appliances remain a durable, well-tolerated middle ground for the majority of patients with mild-to-moderate disease.

Conclusion

The Bern data, covering 300 real-world patients, confirm that mandibular advancement therapy delivers roughly 50% reductions in AHI and ODI, with response shaped by baseline severity, age, and gender — not by how far the jaw is pushed forward. Combined with surgical alternatives like maxillomandibular advancement for non-responders, patients now have a genuine ladder of options beyond CPAP. The task is matching the right rung to the right patient.

Frequently Asked Questions

How much can a mandibular advancement device reduce sleep apnea?

In the Bern study of 300 patients, average AHI fell by 16.4 events/hour and ODI by 10.8 — approximately a 50% improvement, with the largest reductions in patients who started with more severe apnea.

Does pushing the jaw forward more make a MAD work better?

No. The study found no greater AHI or ODI reduction with more prominent protrusion, so dentists typically advance the jaw only as far as needed to control apneas while minimizing jaw discomfort.

Who responds best to mandibular advancement therapy?

Patients with higher baseline AHI and ODI, women, and younger patients showed the greatest reductions, though the devices helped across the cohort on average.

What if a MAD or CPAP doesn’t work for me?

Maxillomandibular advancement surgery — which moves both jaws forward to permanently enlarge the airway — reduces AHI by more than 50% in most patients and is recommended in international guidelines, though it remains underused.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42680687/
https://pubmed.ncbi.nlm.nih.gov/42593027/
https://pubmed.ncbi.nlm.nih.gov/42590144/
https://pubmed.ncbi.nlm.nih.gov/42583576/
https://pubmed.ncbi.nlm.nih.gov/42549506/